Cassava Sciences Stock Surges on Alzheimer's Article Update

Options traders are targeting SAVA at four times the average intraday amount

Deputy Editor
Nov 4, 2021 at 3:49 PM
facebook twitter linkedin


Cassava Sciences Inc (NASDAQ:SAVAis soaring today, up 46.1% to trade at $82.80 at last glance, after the company said the Journal of Neuroscience found no evidence of data manipulation in its 2012 article describing a new approach to treating Alzheimer's. The article is key to Cassava's lead Alzheimer's treatment, simufilam, after its validity was called into question in August by a Citizen Petition to the U.S. Food and Drug Administration (FDA). Today's news comes ahead of the company's third-quarter earnings report, too, which is due out before the open on Monday, Nov. 8. 

Cassava Sciences stock is now trading at levels not seen since its August nosedive, while jumping above the 120-day moving average for the first time since then as well -- a trendline that coincides with former overhead pressure at the $70 level. In the past week alone, the equity has added 91.6%, though it is worth noting it landed on the Short Sale Restricted (SSR) list today, and that short interest represents a whopping 25.2% of the stock's available float. 

SAVA 1104

Options traders are targeting the equity at full force today, with options volume running at four times what's typically seen at this point. So far, 93,000 calls and 53,000 puts have crossed the tape. The weekly 11/5 100-strike call is the most popular by far, with new positions being bought to open there. 

 

If you are not making money with options, you aren’t buying options like this…

There is no options strategy that more perfectly approaches trading the fastest moving and most volatile stocks available in the marketplace than this one. In fact, there is no strategy that better utilizes put options for optimal returns and a real trading edge over other traders in the exact same market. New options traders fail out at an incredible rate without proper trade research, execution timing, and option picking. Capitalize on Schaeffer’s 100+ years of options trading excellence with the most coveted product launch in company history. Don't waste another second... join us right now before the next round of trades are released!

Schaeffer's Investment Research Stock Pick Report
 


 


 
Special Offers from Schaeffer's Trading Partners